Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Last updated: 2026-02-24 15:53:42 ET
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Late last year, Google briefly took the crown for most powerful AI model in the world with the launch of Gemini 3 Pro — only to be surpassed within ...
A coalition of more than a dozen Republican attorneys general is demanding that a taxpayer-funded scientific organization scrub a politically biased c...
RFK Jr.'s attacks on vaccines go beyond changing the childhood immunization schedule. Now he's taking aim at vaccine R&D itself.
The FDA reversed course and told Moderna it would review its application for a new flu vaccine, after refusing to do so earlier this month
National Park Service also sued for removing rainbow Pride flag from Stonewall national monument in New YorkConservation and historical organizations ...
Nvidia Corp (NASDAQ:NVDA) is expanding its footprint in India through government, academic and venture capital partnerships aligned with the country's...
Your muscle-building blueprint: 3 ways to boost your gains from an exercise science pro
Graham has secured a £69.7m job to deliver a new forensic science facility for the Department of Justice in Northern Ireland. The scheme, known as Pr...